Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | April 01, 2026 | April 03, 2026 |
| Revance Therapeutics, Inc.RVNC · Entity 83521 | Director | May 04, 2022 | May 13, 2022 |
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | Director | June 06, 2023 | June 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2036-04-01 | Direct | 214,400 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 214,400 · Balance 214,400 F1: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Fifth Amended and Restated Non-Employee Director Compensation Program. The Stock Option will vest over three years: 33 1/3 % of the options will vest on the first anniversary of the grant date and the remaining 66 2/3 % will vest ratably on the first day of each calendar quarter thereafter, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Fifth Amended and Restated Non-Employee Director Compensation Program. The Stock Option will vest over three years: 33 1/3 % of the options will vest on the first anniversary of the grant date and the remaining 66 2/3 % will vest ratably on the first day of each calendar quarter thereafter, subject to the Reporting Person's continued service to the Issuer.
Revance Therapeutics, Inc.
Report date May 04, 2022 · Filed May 13, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.12 · Expires 2032-05-03 | Direct | 10,756 |
Reported balance
After 2022-05-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-05-04 · Grant · Acquired 10,756 · Balance 10,756 F1: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Dr. Vickers' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Dr. Vickers' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy.
Tectonic Therapeutic, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2033-06-05 | Direct | 17,643 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,643 · Balance 17,643 F1: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 3, 2026 20:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 214,400 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001635046-26-000005 · primarydocument.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,400 Underlying: Common Stock · 214,400 shares Expires 2036-04-01 F1 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Fifth Amended and Restated Non-Employee Director Compensation Program. The Stock Option will vest over three years: 33 1/3 % of the options will vest on the first anniversary of the grant date and the remaining 66 2/3 % will vest ratably on the first day of each calendar quarter thereafter, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:29 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,643 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001127602-23-018287 · form4.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,643 Underlying: Common Stock · 17,643 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:40 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017244 · form4.xml · derivative · entry 2 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:40 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017244 · form4.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| May 04, 2022 Filed May 6, 2022 22:20 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 11,343 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001479290-22-000064 · wf-form4_165187558274170.xml · derivative · entry 2 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,343 Underlying: Common Stock · 11,343 shares Expires 2032-05-03 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Dr. Vickers' Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 04, 2022 Filed May 6, 2022 22:20 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-22-000064 · wf-form4_165187558274170.xml · nonDerivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,722 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Dr. Vickers' Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| May 04, 2022 Filed May 13, 2022 22:13 UTC Amendment | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 10,756 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001479290-22-000068 · wf-form4a_165247995336599.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,756 Underlying: Common Stock · 10,756 shares Expires 2032-05-03 F1 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Dr. Vickers' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 20:21 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | PurchaseCommon Stock | 4,800 | $8.35 | $40,080.00 |
DisclosureSEC source: 0001127602-21-021729 · form4.xml · nonDerivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:51 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,438 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019828 · form4.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 23:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 7,551 | $0.00 Strike: $27.91 | $0.00 |
DisclosureSEC source: 0001479290-21-000116 · wf-form4_162042929549963.xml · derivative · entry 2 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,551 Underlying: Common Stock · 7,551 shares Expires 2031-05-04 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Dr. Vickers' Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 05, 2021 Filed May 7, 2021 23:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 4,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-21-000116 · wf-form4_162042929549963.xml · nonDerivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,663 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Dr. Vickers' Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 21:09 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $21.91 | $0.00 |
DisclosureSEC source: 0001127602-20-019015 · form4.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 4, 2021 or the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| May 14, 2020 Filed May 15, 2020 22:42 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 12,000 | $0.00 Strike: $19.40 | $0.00 |
DisclosureSEC source: 0001479290-20-000069 · wf-form4_158958252468820.xml · derivative · entry 2 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-05-13 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Dr. Vickers' Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 14, 2020 Filed May 15, 2020 22:42 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-20-000069 · wf-form4_158958252468820.xml · nonDerivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,650 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Dr. Vickers' Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:14 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 9,675 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0000899243-19-016860 · doc4.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,675 Underlying: Common Stock · 9,675 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:11 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 9,000 | $0.00 Strike: $12.82 | $0.00 |
DisclosureSEC source: 0001479290-19-000062 · wf-form4_155753708535400.xml · derivative · entry 2 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-05-08 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 9, 2020, subject to Dr. Vickers' Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:11 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-19-000062 · wf-form4_155753708535400.xml · nonDerivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,650 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 9, 2020, subject to Dr. Vickers' Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:23 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 18,743 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0000899243-19-000842 · doc4.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,743 Underlying: Common Stock · 18,743 shares Expires 2029-01-06 F1 · derivative.exercise_date: The shares vest in 36 equal monthly installments over a three year period following January 7, 2019. Read SEC document |
| May 10, 2018 Filed May 12, 2018 00:31 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 6,000 | $0.00 Strike: $29.15 | $0.00 |
DisclosureSEC source: 0001479290-18-000081 · wf-form4_152608509908794.xml · derivative · entry 2 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-05-09 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 10, 2019, subject to Dr. Vickers' Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 10, 2018 Filed May 12, 2018 00:31 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-18-000081 · wf-form4_152608509908794.xml · nonDerivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,150 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 10, 2019, subject to Dr. Vickers' Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| March 16, 2018 Filed Mar 17, 2018 00:05 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | PurchaseCommon Stock | 900 | $31.20 | $28,080.00 |
DisclosureSEC source: 0001479290-18-000052 · wf-form4_152124512506409.xml · nonDerivative · entry 2 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,150 Read SEC document |
| March 16, 2018 Filed Mar 17, 2018 00:05 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | PurchaseCommon Stock | 2,250 | $31.25 | $70,312.50 |
DisclosureSEC source: 0001479290-18-000052 · wf-form4_152124512506409.xml · nonDerivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Read SEC document |
| May 11, 2017 Filed May 12, 2017 23:50 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $20.90 | $0.00 |
DisclosureSEC source: 0001209191-17-032209 · doc4.xml · derivative · entry 2 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-05-10 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 11, 2018, subject to Dr. Vickers' Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual option grant pursuant to the Compensation Policy. Read SEC document |
| May 11, 2017 Filed May 12, 2017 23:50 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-032209 · doc4.xml · nonDerivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 11, 2018, subject to the Dr. Vickers' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.